| 1. |
- Fabbri, Alice, et al.
(författare)
-
Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
- 2018
-
Ingår i: International Journal of Health Policy and Management. - : Maad Rayan Publishing Company. - 2322-5939. ; 7:6, s. 504-509
-
Tidskriftsartikel (refereegranskat)abstract
- Relationships between health professionals and pharmaceutical manufacturers can unduly influence clinical practice. These relationships are the focus of global transparency efforts, including in Europe. We conducted a descriptive content analysis of the transparency provisions implemented by February 2017 in nine European Union (EU) countries concerning payments to health professionals, with duplicate independent coding of all data. Using an author-generated, semi-structured questionnaire, we collected information from each disclosure policy/code on: target industries, categories of healthcare professionals covered, scope of payments included, location and searchability of the disclosed data. Our analysis shows that although important improvements have been put in place in the past few years, significant gaps remain in disclosure requirements and their implementation. The situation differs substantially from country to country and the most striking differences are between governmental and self-regulatory approaches, especially with regard to the comprehensiveness of the disclosed data. In many cases, individuals can still opt out and reporting is incomplete, with common influential gifts such as food and drink excluded. Finally, in several countries data are only available as separate PDFs from companies, thus making the payment reports difficult to access and analyse. In order to overcome these gaps, minimum standards for disclosures should be implemented across Europe. All payments to healthcare professionals and organizations should be included, all health-related industries should be required to submit reports, and usability of disclosed data should be guaranteed.
|
|
| 3. |
- Järvinen, Teppo LN, et al.
(författare)
-
Overdiagnosis of bone fragility in the quest to prevent hip fracture
- 2015
-
Ingår i: The BMJ. - : BMJ. - 1756-1833. ; 350
-
Tidskriftsartikel (refereegranskat)abstract
- Clinical contextHip fractures cause considerable morbidity and mortality and are associated with high healthcare costs. With a growing elderly population their incidence is predicted to riseDiagnostic changeBefore the late 1980s, osteoporosis was diagnosed after a bone fracture. A new definition was introduced in 1994 based on low bone mineral density, expanding indications for pharmacotherapy. The introduction of fracture risk calculators exacerbated the trendRationale for changeFractures are a function of bone fragility, which is measureable and can be improved with drugsLeap of faithIdentifying and treating patients with fragile bones is a cost effective strategy to prevent fractures, particularly hip fracturesImpact on prevalenceCurrent fracture risk predictors have at least doubled the number of candidates for drug treatment. Under US guidelines about 75% of white women aged over 65 years have become candidates for drug treatmentEvidence of overdiagnosisRates of hip fracture continue to decline, and most occur in people without osteoporosis. Our meta-analysis indicates that 175 postmenopausal women with bone fragility must be treated for about three years to prevent one hip fractureHarms from overdiagnosisBeing labelled as at risk of fracture imposes a psychological burden. Drug treatment is associated with adverse events, such as gastrointestinal problems, atypical femoral fractures, and osteonecrosis of the jawLimitations of evidenceHip fractures are caused predominantly by falls in frail older adults. Few studies on preventive pharmacotherapy included adults aged ≥80, but evidence suggests no treatment benefit. Evidence is also sparse on treatment of men and optimum duration of treatment
|
|
